Mochida Pharmaceutical Co., Ltd.
Notice Regarding Share Buyback Status
The target shares for buyback are our common shares, total 82,000 shares, aggregate purchase price 264,719,000 yen. Buyback period is from August 1, 2026 to August 31, 2026 (on a contracted basis), conducted via market purchases. Based on the Board of Directors resolution dated March 30, 2026, the cap is 530,000 shares (1.50% of outstanding shares) and up to 2,000,000,000 yen, with the period from May 18, 2026 to December 18, 2026; cumulatively as of August 31, 2026, 268,500 shares have been acquired for a total of 868,284,000 yen.
Key Figures
- Total number of shares acquired: 82,000 shares (Total purchase price: 264,719,000 yen)
- Cumulative total shares acquired: 268,500 shares (Cumulative total purchase price: 868,284,000 yen)
- Acquisition period: August 1, 2026 to August 31, 2026 (on a contracted basis)
AI要約
Overview of the Share Buyback
According to the announced share buyback status, the target shares are common shares, and 82,000 shares were acquired at 264,719,000 yen through Tokyo Stock Exchange market purchases from August 1, 2026 to August 31, 2026 (on a contracted basis). Based on the Board of Directors resolution dated March 30, 2026, the cap is 530,000 shares (1.50% of issued shares), up to 2,000,000,000 yen, with the period from May 18, 2026 to December 18, 2026, and cumulatively as of August 31, 2026, 268,500 shares have been acquired for a total of 868,284,000 yen.
Outlook and impact on shareholders
The cumulative total acquired this time may represent about 50.6% of the limit; however, actual acquisitions depend on market conditions and remain uncertain. Share buybacks are viewed as part of a policy to enhance shareholder value and may help mitigate dilution and strengthen shareholder returns. Going forward, disclosures on progress of acquisitions and alignment with capital policy will be closely watched.
Mochida Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
